66. IgA nephropathy Clinical trials / Disease details
Clinical trials : 275 / Drugs : 258 - (DrugBank : 82) / Drug target genes : 36 - Drug target pathways : 140
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05596708 (ClinicalTrials.gov) | March 1, 2023 | 25/10/2022 | Study of Telitacicept in Patients With Refractory IgA Nephropathy | A Single-arm, Forward-looking, Exploratory Clinical Study of Telitacicept in Patients With Refractory IgA Nephropathy | IgA Nephropathy | Drug: Telitacicept | Second Affiliated Hospital, School of Medicine, Zhejiang University | NULL | Not yet recruiting | 18 Years | 70 Years | All | 40 | Phase 2/Phase 3 | China |
| 2 | NCT04905212 (ClinicalTrials.gov) | November 4, 2021 | 21/5/2021 | A Study of Telitacicept for Injection (RC18) in Subjects With IgA Nephropathy | A Phase 2, Randomized, Double-Blind, Multicenter Study of Telitacicept for Injection (RC18) With an Optional Open Label Extension in Subjects With IgA Nephropathy | IgA Nephropathy | Drug: Telitacicept 160mg;Drug: Telitacicept 240mg;Drug: Placebo | RemeGen Co., Ltd. | NULL | Recruiting | 18 Years | N/A | All | 30 | Phase 2 | United States |